Cholesterol management in theory and practice

Circulation

Volumn 96, Issue 12, 1997, Pages 4424-4430

  Gotto, Antonio M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Atherosclerosis; Cholesterol; Epidemiology; Heart diseases; Lipids

Indexed keywords

ACETYLCHOLINE; ANTIOXIDANT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; COLESTYRAMINE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; PROBUCOL; SIMVASTATIN; TRIACYLGLYCEROL; WARFARIN;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MORTALITY; MYOPATHY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; THEORY; VASODILATATION;

EID: 0344015790     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.12.4424     Document Type: Review

References (53)

1. American Heart Association. Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 1997.
2. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1329-1445.
3. Reaven GM, Chen YD. Insulin resistance, its consequences, and coronary heart disease: must we choose one culprit? Circulation. 1996;93:1780-1783.
4. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol. 1996;7:167-171.
5. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37-45.
6. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-373.
7. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
8. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation. 1995;91:2274-2282.
9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
10. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
11. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with Simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
12. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engt J Med. 1995; 333:1301-1307.
13. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engt J Med. 1996;335:1001-1009.
14. Sacks FM, Gibson CM, Rosner B, Pasternak RC, Stone PH, the Harvard Atherosclerosis Reversibility Project Research Group. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. Am J Cardiol. 1995; 76:78C-85C.
15. Waters DD. Stabilization of Coronary Atherosclerosis. London, England: Science Press; 1994.
16. Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol. 1995;6: 386-388.
17. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, Gordon DJ, Burl VL, Brown CD, Lippel K, Cleeman JI. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA. 1993; 269:3002-3008.
18. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997; 336:153-162.
19. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993; 87:1781-1791.
20. Gotto AM Jr. Lipid lowering, regression, and coronary events: a review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting. Circulation. 1995; 92:646-656.
21. Fuster V, Gotto AM, Libby P, Loscalzo J, McGill HC. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task force 1. Pathogenesis of coronary disease: the biologic role of risk factors. J Am Coll Cardiol. 1996;27:964-976.
22. Ambrose JA, Tannenbaum MA, Alexopoulos D, HjemdahlMonsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V. Angiographic progression or coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12:56-62.
23. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
24. Giroud D, Li JM, Urban P, Meier B, Rutishauser W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol. 1992;69: 729-732.
25. Nobuyoshi M, Tanaka M, Nosaka H, Kimura T, Yokoi H, Hamasaki N, Kim K, Shindo T, Kimura K. Progression of coronary atherosclerosis: is coronary spasm related to progression? J Am Coll Cardiol. 1991;18:904-910.
26. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
27. Treasure CB, Klein JL, Weintraub WS, Talley D, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
28. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, Selwyn AP. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 1997;95:324-328.
29. van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris: REGRESS Study Group. Circulation. 1996; 94:1503-1505.
30. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995; 332:488-493.
31. National Heart, Lung, and Blood Institute (NHLBI) Cholesterol Awareness Surveys. Presented at the Cholesterol Awareness Surveys Press Conference; December 4, 1995; Bethesda, Md.
32. Sempos CT, Cleeman JI, Carroll MD, Johnson CL, Bachorik PS, Gordon DJ, Burt VL, Briefel RR, Brown CD, Lippel K, Rifkind BM. Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA. 1993;269:3009-3014.
33. Bairey Merz CN, Felando MN, Klein J. Cholesterol awareness and treatment in patients with coronary artery disease participating in cardiac rehabilitation. J Cardpulm Rehabil. 1996;16:117-122.
34. Roberts WC. The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease. Am J Cardiol. 1996;78:377-378.
35. Marceline JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996;100: 605-610.
36. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S, for the HERS Research Group. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women in heart disease. JAMA. 1997;277:1281-1286.
37. Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Initm Med. 1988;148: 36-69.
38. Illingworth DR. HMG-CoA rcductase inhibitors. Curr Opin Lipidol. 1991;2:24-30.
39. Farmer JA, Getto AM Jr. Currently available hypolipidaemic drugs and future therapeutic developments. Bailliercs Clin Endocrinol Metab. 1995;9:825-847.
40. Black DM. Atorvastatin: a step ahead for HMG-CoA reductase inhibitors. In: Woodford FP, Davignon J, Sniderman A, eds, Atherosclerosis X. Proceedings of the 10th International Symposium on Atherosclerosis. Montréal, Canada, October 9-14, 1994. New York, NY: Elsevier; 1995:307-310.
41. Data on file. Parke-Davis, Morris Plains, NJ.
42. Goto Y, and Clinical Study Group of BAY w 6228 in Japan. Effects of BAY w 6228 on serum lipid and apoprotein levels in patients with hypercholesterolemia in Japan. Atherosclerosis. 1994;109:256. Abstract.
43. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO, Smith EE III, Weaver WD. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice 7uidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cordial. 1996;28: 1328-1428.
44. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Smith SC Jr, Washington R. When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for Healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation. 1997;95:1683-1685.
45. Ballantyne CM, West MS, Jaax SM, Scott LW, Herd JA, Jones PH, Farmer JA, Gotto AM Jr. Should lipid-lowering drugs be part of initial therapy in the secondary prevention of CHD? J Am Coll Cardiol. 1996;27(suppl A):134A. Abstract.
46. Goldman L, Gordon DJ, Rifkind BM, Hulley SB, Detsky AS, Goodman DW, Kinosian B, Weinstein MC. Cost and health implications of cholesterol lowering. Circulation. 1992;85:1960-1968.
47. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart disease, II: preventive therapies. Prog Cardiovasc Dis. 1995;37:243-271.
48. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther. 1995;17:572-580.
49. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyörälä K, Miettinen T, Haghfelt T, Faergeman O, Thorgeirsson G, Jönsson B, Schwartz JS, for the Scandinavian Simvastatin Survival Study Group. Cholesterol lowering and its use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation. 1996;93:1796-1802.
50. Ashraf T, Hay JW, Pitt B, Wittels E, Grouse J, Davidson M, Furberg CD, Radican L. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996; 78:409-414.
51. Tevat J. Impact and cost-effectiveness of smoking interventions. Am J Med. 1992;93(suppl 1A):43S-47S.
52. Sacks FM, Rouleau JL, Moye LA, Pfeffer MA, Warnica JW, Arnold JM, Nash DT, Brown LE, Sestier F, Rutherford J, Davis BR, Hawkins CM, Braunwald E. Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol. Am J Cardiol. 1995;75:621-623.
53. Pfeffer MA, Sacks FM, Moyé LA, Brown L, Rouleau JL, Hartley LH, Rouleau J, Grimm R, Sestier F, Wickemeyer W, Cole TG, Braunwald E. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. Am J Cardiol. 1995;76: 98C-106C.